CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
Authors
AC Heatherington
CB Miller
+15 more
D Kotasek
DH Henry
GD Demetri
IC Macdougall
IC Macdougall
J Glaspy
J Glaspy
JC Egrie
JC Egrie
JL Gabrilove
N Casadevall
NJ Vogelzang
RE Smith
S Cascinu
TJ Littlewood
Publication date
1 July 2002
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
View
on
PubMed
Abstract
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg(−1) wk(−1) or to a control group receiving epoetin alfa at an initial dose of 150 U kg(−1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g. kg(−1) every 2 weeks or epoetin alfa, initial dose 40 000 U wk(−1). Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy. British Journal of Cancer (2002) 87, 268–276. doi:10.1038/sj.bjc.6600465 www.bjcancer.com © 2002 Cancer Research U
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 11/12/2019
Sustaining member
eScholarship - University of California
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:escholarship.org:ark:/1303...
Last time updated on 25/12/2021